NADPH oxidase inhibitors

A decade of discovery from Nox2ds to HTS

Eugenia Cifuentes-Pagano, Gabor Csanyi, Patrick J. Pagano

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS). Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress. In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function. The study of these enzymes in physiological and pathophysiological conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution. A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors. In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling. However, the complex structures and interactions of these heteromeric isozymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects. Thus, as both therapies and pharmacological tools, molecule-based inhibitors continue to prove extremely useful and rational in design. Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS. Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small molecule inhibitors that have emerged from high-throughput screening campaigns.

Original languageEnglish (US)
Pages (from-to)2315-2325
Number of pages11
JournalCellular and Molecular Life Sciences
Volume69
Issue number14
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

NADPH Oxidase
Protein Isoforms
Reactive Oxygen Species
Tissue Distribution
Isoenzymes
Oxidative Stress
Animal Models
Pharmacology
Enzymes
Proteins

Keywords

  • High-throughput screening
  • Inhibitors
  • NADPH oxidase
  • Nox isoforms
  • Peptides
  • Small molecules

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Molecular Medicine
  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

NADPH oxidase inhibitors : A decade of discovery from Nox2ds to HTS. / Cifuentes-Pagano, Eugenia; Csanyi, Gabor; Pagano, Patrick J.

In: Cellular and Molecular Life Sciences, Vol. 69, No. 14, 01.07.2012, p. 2315-2325.

Research output: Contribution to journalReview article

Cifuentes-Pagano, Eugenia ; Csanyi, Gabor ; Pagano, Patrick J. / NADPH oxidase inhibitors : A decade of discovery from Nox2ds to HTS. In: Cellular and Molecular Life Sciences. 2012 ; Vol. 69, No. 14. pp. 2315-2325.
@article{9df97eb3e4594f759bc0106db6e5435b,
title = "NADPH oxidase inhibitors: A decade of discovery from Nox2ds to HTS",
abstract = "NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS). Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress. In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function. The study of these enzymes in physiological and pathophysiological conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution. A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors. In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling. However, the complex structures and interactions of these heteromeric isozymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects. Thus, as both therapies and pharmacological tools, molecule-based inhibitors continue to prove extremely useful and rational in design. Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS. Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small molecule inhibitors that have emerged from high-throughput screening campaigns.",
keywords = "High-throughput screening, Inhibitors, NADPH oxidase, Nox isoforms, Peptides, Small molecules",
author = "Eugenia Cifuentes-Pagano and Gabor Csanyi and Pagano, {Patrick J.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1007/s00018-012-1009-2",
language = "English (US)",
volume = "69",
pages = "2315--2325",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "14",

}

TY - JOUR

T1 - NADPH oxidase inhibitors

T2 - A decade of discovery from Nox2ds to HTS

AU - Cifuentes-Pagano, Eugenia

AU - Csanyi, Gabor

AU - Pagano, Patrick J.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS). Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress. In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function. The study of these enzymes in physiological and pathophysiological conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution. A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors. In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling. However, the complex structures and interactions of these heteromeric isozymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects. Thus, as both therapies and pharmacological tools, molecule-based inhibitors continue to prove extremely useful and rational in design. Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS. Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small molecule inhibitors that have emerged from high-throughput screening campaigns.

AB - NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS). Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress. In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function. The study of these enzymes in physiological and pathophysiological conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution. A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors. In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling. However, the complex structures and interactions of these heteromeric isozymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects. Thus, as both therapies and pharmacological tools, molecule-based inhibitors continue to prove extremely useful and rational in design. Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS. Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small molecule inhibitors that have emerged from high-throughput screening campaigns.

KW - High-throughput screening

KW - Inhibitors

KW - NADPH oxidase

KW - Nox isoforms

KW - Peptides

KW - Small molecules

UR - http://www.scopus.com/inward/record.url?scp=84864345542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864345542&partnerID=8YFLogxK

U2 - 10.1007/s00018-012-1009-2

DO - 10.1007/s00018-012-1009-2

M3 - Review article

VL - 69

SP - 2315

EP - 2325

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 14

ER -